2022 / 02

Next Paper
DOI: 10.24075/brsmu.2022.015

ORIGINAL RESEARCH

Experience of tocilizumab in hospital patients with moderate COVID-19

Burgasova OA1,2, Dolinniy SV3, Tetova VB1, Ogarkova DA2, Odnoralov MA1, Bakalin VV1, Smetanina SV3, Antipyat NA3, Taranova MV4
About authors

1 Peoples’ Friendship University of Russia, Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

3 Clinical Hospital for Infectious Diseases №1, Moscow, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Correspondence should be addressed: Olga A. Burgasova
Volokolamskoe sh., 47, str. 8, korp. 5, Moscow, 125310, Russia; ur.liam@avosagrubaglo

About paper

Author contribution: OA Burgasova — initiative and design, supervision of the clinical part of the study, writing of the manuscript; SV Dolinniy — literature review, clinical observations, data processing; VB Tetova — literature review, editing of the manuscript; DA Ogarkova — statistical analysis; MA Odnoralov, VV Baсalin — clinical observations, processing of clinical and laboratory data; SV Smetanina — concept; NA Antipyat — supervision of the clinical part of the study, MV Taranova — literature review, data processing.

Compliance with ethical standards: the study was approved by the ethics committee at the Clinical Hospital for Infectious Diseases №1 (Protocol 1 of January 11, 2021); all participants provided informed consent for the study.

Received: 2022-03-10 Accepted: 2022-04-03 Published online: 2022-04-15
|
No data available...